David Grayzel
QuietNamed in filings at Atlas Venture
- Board seats filed
- 7
all filings on record
Named in filings at Atlas Venture
all filings on record
last 24 months
from a verified or cited source
| Comanche Biopharma | Biotech & pharma | December 2023 | None on file |
| Triana Biomedicines | Biotech & pharma | September 2021 | Abingworth Bioventures, Third Rock Ventures |
| Xilio Therapeutics | Biotech & pharma | January 2021 | Bain Capital Life Sciences, SV Life Sciences, Virtuoso-mccarran |
| Aerovate Therapeutics | Biotech & pharma | August 2020 | Sofinnova Venture Partners |
| Affinia Therapeutics | Biotech & pharma | March 2020 | NEA |
| Akriveia Therapeutics | Biotech & pharma | January 2018 | None on file |
| Annovation BioPharma | Biotech & pharma | July 2012 | Partners Innovation |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name David Grayzel on the board, based on 7 filed seats with a verified or cited source.